Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
IR vs HON vs EMR vs ROK vs IEX
Revenue, margins, valuation, and 5-year total return — side by side.
Conglomerates
Industrial - Machinery
Industrial - Machinery
Industrial - Machinery
IR vs HON vs EMR vs ROK vs IEX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Conglomerates | Industrial - Machinery | Industrial - Machinery | Industrial - Machinery |
| Market Cap | $30.35B | $136.91B | $79.02B | $50.37B | $15.97B |
| Revenue (TTM) | $7.78B | $36.76B | $18.32B | $8.80B | $3.53B |
| Net Income (TTM) | $587M | $4.10B | $2.44B | $1.09B | $508M |
| Gross Margin | 38.2% | 36.9% | 52.7% | 52.5% | 44.4% |
| Operating Margin | 18.1% | 14.9% | 19.8% | 19.1% | 20.8% |
| Forward P/E | 22.0x | 20.5x | 21.7x | 36.9x | 25.5x |
| Total Debt | $4.78B | $34.58B | $13.76B | $3.65B | $1.82B |
| Cash & Equiv. | $1.25B | $12.49B | $1.54B | $468M | $580M |
IR vs HON vs EMR vs ROK vs IEX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Ingersoll Rand Inc. (IR) | 100 | 274.8 | +174.8% |
| Honeywell Internati… (HON) | 100 | 148.1 | +48.1% |
| Emerson Electric Co. (EMR) | 100 | 231.2 | +131.2% |
| Rockwell Automation… (ROK) | 100 | 207.4 | +107.4% |
| IDEX Corporation (IEX) | 100 | 134.8 | +34.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IR vs HON vs EMR vs ROK vs IEX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IR lags the leaders in this set but could rank higher in a more targeted comparison.
HON carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 15 yrs, beta 0.74, yield 2.1%
- Beta 0.74, yield 2.1%, current ratio 1.32x
- 7.8% revenue growth vs ROK's 1.0%
- Lower P/E (20.5x vs 36.9x)
Among these 5 stocks, EMR doesn't own a clear edge in any measured category.
ROK is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 341.0% 10Y total return vs IR's 299.5%
- +60.2% vs IR's -0.4%
- 9.7% ROA vs IR's 3.2%, ROIC 15.1% vs 7.8%
IEX ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.
- Rev growth 5.8%, EPS growth -3.5%, 3Y rev CAGR 2.8%
- Lower volatility, beta 0.95, Low D/E 45.2%, current ratio 2.86x
- PEG 4.77 vs HON's 11.18
- 14.4% margin vs IR's 7.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.8% revenue growth vs ROK's 1.0% | |
| Value | Lower P/E (20.5x vs 36.9x) | |
| Quality / Margins | 14.4% margin vs IR's 7.5% | |
| Stability / Safety | Beta 0.74 vs EMR's 1.52 | |
| Dividends | 2.1% yield, 15-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +60.2% vs IR's -0.4% | |
| Efficiency (ROA) | 9.7% ROA vs IR's 3.2%, ROIC 15.1% vs 7.8% |
IR vs HON vs EMR vs ROK vs IEX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IR vs HON vs EMR vs ROK vs IEX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ROK leads in 2 of 6 categories
IEX leads 1 • IR leads 0 • HON leads 0 • EMR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IEX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HON is the larger business by revenue, generating $36.8B annually — 10.4x IEX's $3.5B. IEX is the more profitable business, keeping 14.4% of every revenue dollar as net income compared to IR's 7.5%. On growth, ROK holds the edge at +11.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $7.8B | $36.8B | $18.3B | $8.8B | $3.5B |
| EBITDAEarnings before interest/tax | $1.9B | $6.5B | $4.7B | $1.9B | $945M |
| Net IncomeAfter-tax profit | $587M | $4.1B | $2.4B | $1.1B | $508M |
| Free Cash FlowCash after capex | $1.2B | $4.2B | $3.1B | $1.3B | $611M |
| Gross MarginGross profit ÷ Revenue | +38.2% | +36.9% | +52.7% | +52.5% | +44.4% |
| Operating MarginEBIT ÷ Revenue | +18.1% | +14.9% | +19.8% | +19.1% | +20.8% |
| Net MarginNet income ÷ Revenue | +7.5% | +11.2% | +13.3% | +12.4% | +14.4% |
| FCF MarginFCF ÷ Revenue | +14.9% | +11.4% | +17.0% | +15.2% | +17.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.6% | -6.9% | +2.9% | +11.8% | +8.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.5% | -41.9% | +28.2% | +39.6% | +27.8% |
Valuation Metrics
Evenly matched — IR and HON each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 29.4x trailing earnings, HON trades at a 50% valuation discount to ROK's 58.5x P/E. Adjusting for growth (PEG ratio), IEX offers better value at 6.27x vs HON's 15.99x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $30.4B | $136.9B | $79.0B | $50.4B | $16.0B |
| Enterprise ValueMkt cap + debt − cash | $33.9B | $159.0B | $91.2B | $53.6B | $17.2B |
| Trailing P/EPrice ÷ TTM EPS | 53.45x | 29.36x | 34.92x | 58.45x | 33.51x |
| Forward P/EPrice ÷ next-FY EPS est. | 22.05x | 20.52x | 21.71x | 36.93x | 25.52x |
| PEG RatioP/E ÷ EPS growth rate | — | 15.99x | 7.73x | — | 6.27x |
| EV / EBITDAEnterprise value multiple | 17.61x | 19.99x | 18.07x | 30.64x | 18.58x |
| Price / SalesMarket cap ÷ Revenue | 3.97x | 3.66x | 4.39x | 6.04x | 4.62x |
| Price / BookPrice ÷ Book value/share | 3.06x | 9.00x | 3.94x | 13.66x | 4.02x |
| Price / FCFMarket cap ÷ FCF | 24.88x | 25.39x | 29.63x | 37.09x | 25.89x |
Profitability & Efficiency
ROK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ROK delivers a 29.6% return on equity — every $100 of shareholder capital generates $30 in annual profit, vs $6 for IR. IEX carries lower financial leverage with a 0.45x debt-to-equity ratio, signaling a more conservative balance sheet compared to HON's 2.24x. On the Piotroski fundamental quality scale (0–9), ROK scores 8/9 vs HON's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +5.8% | +23.1% | +12.1% | +29.6% | +12.6% |
| ROA (TTM)Return on assets | +3.2% | +5.3% | +5.8% | +9.7% | +7.3% |
| ROICReturn on invested capital | +7.8% | +12.6% | +8.2% | +15.1% | +10.4% |
| ROCEReturn on capital employed | +8.7% | +12.6% | +10.0% | +18.5% | +11.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 7 | 8 | 7 |
| Debt / EquityFinancial leverage | 0.47x | 2.24x | 0.68x | 0.98x | 0.45x |
| Net DebtTotal debt minus cash | $3.5B | $22.1B | $12.2B | $3.2B | $1.2B |
| Cash & Equiv.Liquid assets | $1.2B | $12.5B | $1.5B | $468M | $580M |
| Total DebtShort + long-term debt | $4.8B | $34.6B | $13.8B | $3.6B | $1.8B |
| Interest CoverageEBIT ÷ Interest expense | 4.53x | 3.92x | 6.46x | 9.06x | 11.33x |
Total Returns (Dividends Reinvested)
ROK leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ROK five years ago would be worth $17,462 today (with dividends reinvested), compared to $10,068 for IEX. Over the past 12 months, ROK leads with a +60.2% total return vs IR's -0.4%. The 3-year compound annual growth rate (CAGR) favors EMR at 20.7% vs IEX's 1.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -2.8% | +10.9% | +4.3% | +12.8% | +20.4% |
| 1-Year ReturnPast 12 months | -0.4% | +2.8% | +30.4% | +60.2% | +20.9% |
| 3-Year ReturnCumulative with dividends | +31.9% | +16.2% | +75.9% | +65.0% | +5.9% |
| 5-Year ReturnCumulative with dividends | +54.1% | +3.3% | +59.5% | +74.6% | +0.7% |
| 10-Year ReturnCumulative with dividends | +299.5% | +135.1% | +206.6% | +341.0% | +189.3% |
| CAGR (3Y)Annualised 3-year return | +9.7% | +5.1% | +20.7% | +18.2% | +1.9% |
Risk & Volatility
Evenly matched — HON and ROK each lead in 1 of 2 comparable metrics.
Risk & Volatility
HON is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than EMR's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ROK currently trades 96.7% from its 52-week high vs IR's 76.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.48x | 0.74x | 1.52x | 1.33x | 0.95x |
| 52-Week HighHighest price in past year | $100.96 | $248.18 | $165.15 | $463.49 | $223.84 |
| 52-Week LowLowest price in past year | $72.45 | $186.76 | $108.37 | $277.66 | $157.25 |
| % of 52W HighCurrent price vs 52-week peak | +76.8% | +87.1% | +85.4% | +96.7% | +96.0% |
| RSI (14)Momentum oscillator 0–100 | 43.3 | 45.1 | 61.3 | 74.9 | 67.6 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 3.7M | 2.8M | 831K | 713K |
Analyst Outlook
Evenly matched — HON and EMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: IR as "Buy", HON as "Buy", EMR as "Buy", ROK as "Hold", IEX as "Hold". Consensus price targets imply 28.4% upside for IR (target: $100) vs -2.6% for ROK (target: $437). For income investors, HON offers the higher dividend yield at 2.14% vs IR's 0.10%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $99.50 | $243.83 | $161.92 | $436.56 | $242.14 |
| # AnalystsCovering analysts | 15 | 28 | 41 | 39 | 29 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | +2.1% | +1.5% | +1.2% | +1.3% |
| Dividend StreakConsecutive years of raises | 0 | 15 | 37 | 20 | 23 |
| Dividend / ShareAnnual DPS | $0.08 | $4.63 | $2.10 | $5.23 | $2.82 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.4% | +2.8% | +1.6% | +0.8% | +1.6% |
ROK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). IEX leads in 1 (Income & Cash Flow). 3 tied.
IR vs HON vs EMR vs ROK vs IEX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IR or HON or EMR or ROK or IEX a better buy right now?
For growth investors, Honeywell International Inc.
(HON) is the stronger pick with 7. 8% revenue growth year-over-year, versus 1. 0% for Rockwell Automation, Inc. (ROK). Honeywell International Inc. (HON) offers the better valuation at 29. 4x trailing P/E (20. 5x forward), making it the more compelling value choice. Analysts rate Ingersoll Rand Inc. (IR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IR or HON or EMR or ROK or IEX?
On trailing P/E, Honeywell International Inc.
(HON) is the cheapest at 29. 4x versus Rockwell Automation, Inc. at 58. 5x. On forward P/E, Honeywell International Inc. is actually cheaper at 20. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IDEX Corporation wins at 4. 77x versus Honeywell International Inc. 's 11. 18x.
03Which is the better long-term investment — IR or HON or EMR or ROK or IEX?
Over the past 5 years, Rockwell Automation, Inc.
(ROK) delivered a total return of +74. 6%, compared to +0. 7% for IDEX Corporation (IEX). Over 10 years, the gap is even starker: ROK returned +341. 0% versus HON's +135. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IR or HON or EMR or ROK or IEX?
By beta (market sensitivity over 5 years), Honeywell International Inc.
(HON) is the lower-risk stock at 0. 74β versus Emerson Electric Co. 's 1. 52β — meaning EMR is approximately 105% more volatile than HON relative to the S&P 500. On balance sheet safety, IDEX Corporation (IEX) carries a lower debt/equity ratio of 45% versus 2% for Honeywell International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — IR or HON or EMR or ROK or IEX?
By revenue growth (latest reported year), Honeywell International Inc.
(HON) is pulling ahead at 7. 8% versus 1. 0% for Rockwell Automation, Inc. (ROK). On earnings-per-share growth, the picture is similar: Emerson Electric Co. grew EPS 17. 8% year-over-year, compared to -29. 6% for Ingersoll Rand Inc.. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IR or HON or EMR or ROK or IEX?
IDEX Corporation (IEX) is the more profitable company, earning 14.
0% net margin versus 7. 6% for Ingersoll Rand Inc. — meaning it keeps 14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IEX leads at 20. 8% versus 17. 1% for ROK. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IR or HON or EMR or ROK or IEX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, IDEX Corporation (IEX) is the more undervalued stock at a PEG of 4. 77x versus Honeywell International Inc. 's 11. 18x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Honeywell International Inc. (HON) trades at 20. 5x forward P/E versus 36. 9x for Rockwell Automation, Inc. — 16. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IR: 28. 4% to $99. 50.
08Which pays a better dividend — IR or HON or EMR or ROK or IEX?
All stocks in this comparison pay dividends.
Honeywell International Inc. (HON) offers the highest yield at 2. 1%, versus 0. 1% for Ingersoll Rand Inc. (IR).
09Is IR or HON or EMR or ROK or IEX better for a retirement portfolio?
For long-horizon retirement investors, Honeywell International Inc.
(HON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), 2. 1% yield, +135. 1% 10Y return). Both have compounded well over 10 years (HON: +135. 1%, IR: +299. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IR and HON and EMR and ROK and IEX?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
HON, EMR, ROK, IEX pay a dividend while IR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.